GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Avidity Biosciences
Avidity Biosciences is a biotech company developing a new class of RNA therapeutics. Its stock price is highly volatile and dependent on early clinical trial results. The chart reflects the high risk and potential reward associated with this breakthrough scientific platform.
Share prices of companies in the market segment - Dna
Avidity Biosciences is developing a new class of RNA therapeutics. We classify the company as part of the DNA sector. The chart below shows the overall dynamics of this biotech segment, reflecting investor sentiment regarding breakthrough genetic technologies.
Broad Market Index - GURU.Markets
Avidity Biosciences is a biotech company developing a new class of RNA-based therapeutics that can deliver drugs directly to diseased cells. As an innovator in genetic medicine, it is included in our GURU.Markets index. The chart below reflects the overall stock market performance. Compare it to Avidity shares to assess the outlook for the biotech sector.
Change in the price of a company, segment, and market as a whole per day
RNA - Daily change in the company's share price Avidity Biosciences
Avidity Biosciences (RNA), a biotech company developing RNA therapeutics, has a Change_Co that is highly sensitive to clinical trial results and drug development milestones. RNA volatility is a measure inherent to innovative biotech companies. In our formulas, this metric is important for assessing risks and potential in the DNA/RNA therapeutics sector.
Daily change in the price of a set of shares in a market segment - Dna
Avidity Biosciences, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with RNA's performance, which depends on the results of clinical trials of its RNA therapy, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Avidity Biosciences is a pioneer in developing a new class of RNA therapeutics. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with Avidity's technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Avidity Biosciences
Avidity is a biotech company developing RNA interference-based drugs. The company's shares are a bet on a breakthrough in gene therapy. Their high, speculative volatility is part of the dynamic of the innovation sector.
Annual dynamics of market capitalization of the market segment - Dna
Avidity Biosciences, Inc. is a biotechnology company developing a new class of RNA therapeutics. Its innovative platform is aimed at treating previously inaccessible diseases. Its stock price reflects the high potential of its technology and the risks associated with clinical trials, which are typical for the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Avidity Biosciences is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the key events are data releases, not macroeconomic statistics.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Avidity Biosciences
The performance of Avidity Biosciences, a biopharmaceutical company, depends on its scientific platform. Monthly fluctuations on the chart reflect not sales, but rather news about clinical trials of its RNA-based therapeutics, the successful results of which could validate the potential of its entire technology.
Monthly dynamics of market capitalization of the market segment - Dna
This chart reflects the dynamics of the biotech sector, particularly the RNA therapeutics segment. For Avidity, with its innovative platform, it serves as a backdrop. Its movements demonstrate how positive data from early clinical trials can create high expectations for the entire niche.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Avidity Biosciences is a biotech company pioneering the development of a new class of RNA-based therapeutics (AOCs) that can deliver drugs directly to diseased cells. The chart below shows general market trends. Does Avidity live in a world where scientific breakthroughs are king?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Avidity Biosciences
Avidity Biosciences' weekly performance is a heartbeat of biotech innovation. Every surge or decline in price reflects investor anticipation of news about clinical trials of its RNA therapy platform. The chart below is a visual story of high risk and potential breakthroughs in treating rare diseases.
Weekly dynamics of market capitalization of the market segment - Dna
Avidity Biosciences operates in the biotech sector, where weekly stock price fluctuations often mirror those of the industry as a whole. Important scientific conferences or FDA decisions on a single drug can trigger a wave of optimism or pessimism across the entire sector. This chart shows how Avidity is moving with this volatile innovation market.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Biotech stocks like Avidity often exist in their own universe, responding to clinical trial data rather than GDP or inflation. The chart clearly demonstrates how isolated the company's weekly performance is from broader market fluctuations. Does it ignore market noise, or does it follow it during quiet moments?
Market capitalization of the company, segment and market as a whole
RNA - Market capitalization of the company Avidity Biosciences
Avidity Biosciences' market capitalization curve isn't a sales chart, but rather the pulse of biotech hope. Its every rise and fall is directly linked to clinical trial news. The chart below shows how investors assess the potential of AOC's unique platform for developing revolutionary RNA therapies.
RNA - Share of the company's market capitalization Avidity Biosciences within the market segment - Dna
Avidity Biosciences is an ambitious player in the gene therapy sector. Its share of the segment's total market capitalization is still small, typical for a biopharmaceutical company in clinical development. This dynamic reflects investors' bets on AOC's breakthrough technology, which could radically change the landscape of rare disease treatment.
Market capitalization of the market segment - Dna
Avidity Biosciences is developing a new class of RNA therapeutics. But how big is the entire arena where gene therapy developers compete? The chart below shows the overall market capitalization of this revolutionary sector. Its dynamics reflect investors' belief that treating diseases at the DNA level will become the new standard of medicine.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Avidity Biosciences chart doesn't reflect current sales. It's a visualization of hope and biotech risk. The company's market cap reflects the market's bet on the success of its breakthrough RNA therapy delivery platform. Every peak and trough on the chart represents investors' reaction to news of clinical trials that will shape the company's future.
Book value capitalization of the company, segment and market as a whole
RNA - Book value capitalization of the company Avidity Biosciences
For biotech company Avidity Biosciences, whose core assets are science and patents, book value reveals the size of its physical assets: laboratories, equipment, and financial reserves. This foundation underpins all research. The chart shows the pace at which the company has grown its physical assets to support innovation.
RNA - Share of the company's book capitalization Avidity Biosciences within the market segment - Dna
In the world of biotechnology, Avidity Biosciences' tangible assets are cutting-edge laboratories and production facilities for developing RNA therapeutics. Every square meter of these facilities is filled with unique equipment that defines the future of medicine. The diagram shows the share of these high-tech physical resources the company possesses in its niche.
Market segment balance sheet capitalization - Dna
Avidity Biosciences' value lies not in its plants, but in its breakthrough scientific platform for delivering RNA therapeutics. This makes its business capital-light, where intellectual property is king. The chart below shows the capital intensity of the entire biotech sector, demonstrating the intangible nature of its assets.
Book value of all companies included in the broad market index - GURU.Markets
Avidity Biosciences operates at the forefront of gene therapy. Its book value, comprised of its laboratories and equipment, may seem modest compared to the overall market. However, this stake in BCap_All is a launchpad for creating intellectual assets that could transform medicine and generate enormous value in the future.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Avidity Biosciences
Avidity Biosciences' balance sheet is the value of its laboratories. Its market capitalization is the promise of a revolution in medicine. The company's massive market valuation over its book value demonstrates that investors aren't buying test tubes and microscopes, but the potential of its unique RNA drug delivery platform, which could change the lives of millions.
Market to book capitalization ratio in a market segment - Dna
Avidity Biosciences is a biotech company whose core value lies in its intellectual property for RNA therapeutics. This metric clearly demonstrates how much the market valuation, based on the future potential of the drugs, exceeds the value of tangible assets such as laboratories and equipment.
Market to book capitalization ratio for the market as a whole
Avidity Biosciences is a biotech company developing a new class of RNA therapeutics. Its value lies almost entirely in its scientific potential and intellectual property. Compared to average market valuations, as shown in this chart, Avidity's premium appears enormous, as investors are betting on the future success of its platform.
Debts of the company, segment and market as a whole
RNA - Company debts Avidity Biosciences
Avidity Biosciences, a pioneer in RNA therapeutics, has a debt policy that is closely tied to funding long-term, capital-intensive R&D. Managing its liabilities allows the company to advance its unique antibody-oligonucleotide conjugates through preclinical and clinical trials, turning scientific breakthroughs into potential treatments for patients with rare diseases.
Market segment debts - Dna
Avidity Biosciences operates in the biotech sector, where research and development require years and significant investment. Traditional debt is rare for clinical-stage companies; they more often raise equity capital. This chart shows whether the company uses debt, which is uncommon in the sector, to accelerate the market launch of its drugs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Avidity Biosciences
Avidity Biosciences operates at the forefront of gene therapy, where the journey from a scientific idea to an approved drug requires colossal investments in R&D. This chart reflects the company's financial strategy: whether it relies on equity or leverages capital, which in early-stage biotech is a sign of either great confidence or high risk.
Market segment debt to market segment book capitalization - Dna
Avidity Biosciences is a biotech company working at the forefront of RNA therapeutics. This sector requires significant investment in research. The chart below reflects the financial health of the entire industry: is its debt burden growing to fund breakthrough developments, or is its capital outstripping its liabilities? This is key to assessing Avidity's financial strength.
Debt to book value of all companies in the market
Avidity Biosciences operates at the forefront of biotechnology, where success is directly dependent on R&D funding. The chart below shows the overall debt levels of all public companies, reflecting the global economic climate. This provides context for understanding how the risky biotech sector fares against the backdrop of the overall market appetite for debt capital.
P/E of the company, segment and market as a whole
P/E - Avidity Biosciences
For Avidity Biosciences, a clinical-stage biopharmaceutical company, traditional earnings estimates are not paramount. This metric reflects not so much current revenue as investor confidence in the breakthrough potential of its RNA therapeutic platform. Price fluctuations here reflect the market's reaction to research results, not financial statements.
P/E of the market segment - Dna
The biopharmaceutical sector, where Avidity Biosciences operates, is particularly valued. This chart reflects the average profitability estimate for mature companies in the industry. For Avidity, which is in the research stage and has no current revenue, this metric provides a benchmark for how the market might value it in the future should its developments be commercially successful.
P/E of the market as a whole
Avidity Biosciences is a biotech company developing a new class of RNA therapeutics. Its valuation depends entirely on the success of clinical trials and investor confidence in its scientific platform. Overall market sentiment, reflected in this chart, has little impact on its value, which is driven by lab news rather than economic data.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Avidity Biosciences
Avidity Biosciences is at the forefront of developing RNA therapeutics aimed at treating previously inaccessible diseases. For a biopharmaceutical company without stable revenue, this chart reflects investor expectations for future clinical success. It shows the potential profitability analysts are pricing in based on research news.
%20P%2FE%20Avidity%20Biosciences&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Avidity-Biosciences&v=1772513554480 "Chart of the company's future (projected) P/E Avidity Biosciences")
Future (projected) P/E of the market segment - Dna
Avidity Biosciences is a pioneer in developing a new class of RNA therapeutics targeting previously inaccessible targets. This indicator compares the company's future profitability expectations with the overall sentiment in the biotech industry. For a research-stage company, this shows how much investors believe in its technology platform compared to its competitors.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772513554603 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Avidity Biosciences is developing a new class of RNA therapeutics for rare diseases. This chart reflects analysts' aggregate earnings expectations. For an early-stage biotech like Avidity, whose value is based on future potential rather than current revenue, a positive market environment is crucial to attracting investment for long-term and expensive research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513554673 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Avidity Biosciences
Avidity Biosciences is a biotech company at the forefront of gene therapy, developing a new class of RNA therapeutics. This chart illustrates the financial side of innovation: the company is actively investing in research and clinical trials, and its current results reflect the costs of developing drugs that could revolutionize medicine in the future.
Profit of companies in the market segment - Dna
Avidity Biosciences is a biotechnology company developing a new class of RNA therapeutics. Its work is at the cutting edge of science and requires colossal investment in research. This chart shows the total profitability of companies in the field of genetic engineering, allowing us to assess the success and commercial viability of breakthroughs in this complex field.
Overall market profit
Avidity Biosciences is a biotech company at the forefront of RNA therapeutics. While its success depends on scientific breakthroughs rather than business cycles, the overall health of the corporate sector influences its future. A healthy economy, reflected in this chart, ensures an influx of venture capital into the industry, which is vital for lengthy and expensive clinical trials.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Avidity Biosciences
Avidity Biosciences is a biotech company working at the forefront of RNA therapeutics. Its future depends entirely on the success of clinical trials and the approval of breakthrough drugs. This chart shows the analyst consensus forecast, which is essentially Wall Street's bet that the company's research will translate into real profits.
%20profit%20of%20the%20company%20Avidity%20Biosciences&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Avidity-Biosciences&v=1772513554810 "Graph of future (projected) profit of the company Avidity Biosciences")
Future (predicted) profit of companies in the market segment - Dna
Avidity Biosciences is at the forefront of gene therapy, developing technology to deliver RNA drugs directly to diseased cells. This chart illustrates the highly volatile profitability forecasts for the biotech sector, where the success of a single company like Avidity could dramatically alter industry expectations if its breakthrough drugs are approved.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772513554890 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Avidity Biosciences is at the forefront of gene therapy, developing a new class of RNA therapeutics. Unlike mature industries, its success is less dependent on the current economic cycle, as reflected in the chart. However, overall market profit expectations influence investor risk appetite and the availability of capital to fund breakthrough, albeit time-consuming, research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513554972 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Avidity Biosciences
Avidity Biosciences is a clinical-stage biotech company developing a new class of RNA therapeutics. Because the company doesn't yet have stable sales, this chart is especially important. It reflects not so much current revenue as investor expectations for future breakthroughs and the commercial potential of its scientific platforms.
P/S market segment - Dna
Avidity Biosciences is a biotech company developing a new class of RNA therapeutics. In this industry, investors often look to the future, assessing the technology's potential rather than current sales. This indicator reflects the industry's average revenue estimate, allowing us to understand whether the market is pricing Avidity at a premium for its innovative approach compared to competitors like Paston.
P/S of the market as a whole
Avidity Biosciences is a biotech company at the forefront of RNA therapeutics, where current revenue is merely a promise of future drugs. Therefore, its valuation may seem anomalous. The graph of average market revenue valuations shows how much expectations for the biotech outpace the actual cash flows of most public companies, which drives its value.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Avidity Biosciences
Avidity Biosciences is a pioneer in developing RNA therapeutics targeting rare diseases. For a company whose value lies in the future success of its drugs, this chart is especially important. It demonstrates how investors assess the potential revenue from its innovative AOC platform in light of news about clinical trials and partnerships.
%20P%2FS%20Avidity%20Biosciences&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Avidity-Biosciences&v=1772513555079 "The graph of the company's future (projected) P/S Avidity Biosciences")
Future (projected) P/S of the market segment - Dna
Avidity Biosciences is developing a new class of RNA therapeutics targeting previously intractable diseases. For a development-stage biotech, this graph reflects investors' confidence in the future commercial success of its platform. It balances the enormous expectations of breakthrough science with the high risks inherent in the entire sector.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772513555143 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Avidity Biosciences is developing a new class of RNA therapeutics for the treatment of rare muscle diseases. This chart shows the overall revenue expectations, and Avidity is a prime example of the source of these expectations. The success of their innovative platform could not only transform patients' lives but also create an entirely new multi-billion dollar market, dramatically impacting the outlook for the entire biopharma industry.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513555196 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Avidity Biosciences
Avidity Biosciences is a clinical-stage biotech company. Because it doesn't yet have commercial products, this chart shows revenue from strategic partnerships and licensing agreements, not sales. The trend reflects the company's funding for its RNA therapeutics research.
Sales of companies in the market segment - Dna
Avidity Biosciences is at the forefront of gene therapy, developing a new class of RNA therapeutics. Each successful clinical trial stage has the potential to radically change approaches to treating rare diseases. This momentum reflects the cumulative investment and hopes placed in the biotech sector, where a single breakthrough can create a multi-billion dollar market.
Overall market sales
Avidity Biosciences operates in the cutting-edge biotechnology sector, developing RNA therapeutics. Overall market revenue trends indirectly impact the company through the investment climate. During periods of economic growth, investors are more willing to invest in long-term, risky projects, such as Avidity's clinical trials, accelerating the development of life-saving drugs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Avidity Biosciences
Avidity Biosciences is a biotech company pioneering RNA therapeutics. As its drugs are in development, this chart represents analyst consensus estimates for the future commercial success of its innovative platform. It demonstrates the market's confidence in the company's ability to bring breakthrough treatments for rare genetic diseases to market.
%20sales%20of%20the%20company%20Avidity%20Biosciences&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Avidity-Biosciences&v=1772513555338 "Schedule of future (projected) sales of the company Avidity Biosciences")
Future (projected) sales of companies in the market segment - Dna
Avidity Biosciences is at the forefront of RNA therapeutics, developing a fundamentally new class of drugs. The company is targeting diseases previously considered incurable. This chart displays forecasts for the entire gene therapy segment. It's an opportunity to see whether industry analysts' expectations align with the revolutionary potential of Avidity's technologies.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772513555380 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
For Avidity Biosciences, a biopharmaceutical company working at the forefront of gene therapy, this chart is important as an indicator of the overall investment climate. Expectations for economic growth and total revenue, reflected here, boost investor confidence and willingness to fund long-term innovative projects that shape the company's future.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513555389 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Avidity Biosciences
Avidity Biosciences is at the forefront of gene therapy, developing a new class of RNA therapeutics. Developing such technologies requires significant investment in R&D. This metric reflects the company's financial health at the clinical trial stage, when the primary objective is not profit generation but efficient capital management to achieve scientific breakthroughs.
Market segment marginality - Dna
Avidity Biosciences is a pioneer in RNA therapeutics, developing a new class of drugs to treat diseases previously considered incurable at the genetic level. The data presented allows us to assess how successfully the company manages its resources compared to other players in the biotech sector. Exceeding industry averages may indicate the commercial potential of their scientific platform.
Market marginality as a whole
Avidity Biosciences is at the forefront of gene therapy, developing RNA-based drugs. While this chart reflects the current profitability of established corporations, Avidity's story is a bet on the future. Their financial metrics now represent an investment in a breakthrough that could radically change the profitability of the entire industry.
Employees in the company, segment and market as a whole
Number of employees in the company Avidity Biosciences
For Avidity Biosciences, a biopharmaceutical company developing cutting-edge gene therapy, this chart demonstrates the growth of its key asset—scientific intellect. The increase in headcount directly reflects progress in clinical trials and the expansion of research, as each new drug represents years of work by talented scientists and specialists.
Share of the company's employees Avidity Biosciences within the market segment - Dna
Avidity Biosciences is an innovator in the field of RNA therapeutics, where intellect is the primary asset. The data presented reflects the company's concentration of scientific talent in the field of genetic engineering. This is a direct indicator of its research capacity and the scale of its ambitions in developing next-generation drugs compared to its competitors in the sector.
Number of employees in the market segment - Dna
Avidity Biosciences is a biotechnology company developing a new class of RNA therapeutics. This chart shows the company's key asset—its scientific and research staff. Employee growth is directly related to progress in clinical trials and the expansion of its development pipeline, demonstrating to investors the intensity of its investment in intellectual capital.
Number of employees in the market as a whole
Avidity Biosciences is a biotech company working at the cutting edge of RNA therapeutics. Its growth depends on scientific breakthroughs, not general economic trends. This chart shows overall employment, but it is in niches like Avidity's that future technological breakthroughs are emerging, requiring unique talent and creating the jobs of tomorrow.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Avidity Biosciences (RNA)
Avidity Biosciences is at the forefront of gene therapy. A small team of highly skilled scientists creates intellectual property—patents for revolutionary drugs. That's why this chart shows an astronomical valuation: the market is pricing the company based on future revenue from its unique developments, not its current workforce.
%20of%20the%20company%20Avidity%20Biosciences%20(RNA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Avidity-Biosciences-RNA&v=1772513555738 "Chart of market capitalization per employee (in thousands of dollars) of the company Avidity Biosciences (RNA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Avidity Biosciences is a clinical-stage biotech company developing a new class of RNA therapeutics. This chart shows the average market cap per employee in the biotech sector. For Avidity, it reflects the market's confidence in their scientific platform and the potential of future drugs, essentially assessing the value of each of their scientists relative to their competitors.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772513555754 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Avidity Biosciences specializes in developing a new class of RNA therapeutics. This chart shows how investors value the company's research-intensive business. High market capitalization per employee is often characteristic of biotech, where the intellectual property and potential of a single discovery can be worth more than large production assets.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513555790 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Avidity Biosciences (RNA)
Avidity Biosciences is a biotech company working at the forefront of RNA therapeutics. Here, value is created not on the assembly line, but in the lab. This metric reflects how a small team of top-notch scientists generates (or spends on R&D) capital, creating intellectual property. It's a bet on a future blockbuster, where a single employee could be worth billions.
%20Chart%20Avidity%20Biosciences%20(RNA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Avidity-Biosciences-RNA&v=1772513555815 "Company Profit Per Employee (in thousands of dollars) Chart Avidity Biosciences (RNA)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Avidity Biosciences is a biotech company developing a platform for delivering RNA therapeutics. This chart shows the benchmark for the "DNA" (Biotech) segment. It's important to understand: for most companies in this sector, this figure is *negative*. These are "R&D ventures," not profitable businesses. This industry benchmark shows how much money, on average, one employee (scientist) "burns" (invests) in the race for the next blockbuster.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772513555926 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Avidity Biosciences (RNA) is a biotech company developing a new class of drugs (AOC) that deliver RNA therapeutics to previously inaccessible cells. This is cutting-edge science. This graph, showing average profit per employee, is important for biotech. It allows us to assess how much a sector where a handful of scientists can create a multi-billion-dollar drug outperforms the "average" labor efficiency.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513555985 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Avidity Biosciences (RNA)
Avidity Biosciences is a biotech company at the forefront of RNA science. Because the company is in the research stage, this chart illustrates potential rather than current sales. Any surge in revenue generated by a small team of scientists could signal a breakthrough partnership or a major milestone in drug development.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Avidity-Biosciences-RNA&v=1772513556024 "Sales chart per company employee Avidity Biosciences (RNA)")
Sales per employee in the market segment - Dna
Avidity Biosciences is a pioneer in RNA therapeutics, developing a new class of drugs. In biotech, where R&D costs are enormous, the transition to commercialization requires maximum operational efficiency. This chart shows the benchmark revenue per employee in the sector. It helps understand how productive Avidity's team is compared to other companies working at the cutting edge of science.
Sales per employee for the market as a whole
Avidity Biosciences is a pioneer in RNA therapeutics. Their staff is predominantly scientists, and the company has long relied on R&D. For investors, it's important to see how this investment in intellectual capital is beginning to pay off. This chart illustrates this transformation: how revenue (from partnerships or initial sales) is beginning to grow per employee.
Short shares by company, segment and market as a whole
Shares shorted by company Avidity Biosciences (RNA)
Avidity Biosciences is a clinical-stage biotech developing a novel class of RNA-based therapeutics (AOCs) for the treatment of rare muscle diseases. This sector is extremely risky. This chart shows the volume of bets against the company by investors who doubt the success of clinical trials or fear the long road to commercialization.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Avidity-Biosciences-RNA&v=1772513556246 "Short Shares Chart for the Company Avidity Biosciences (RNA)")
Shares shorted by market segment - Dna
Avidity Biosciences is developing a new class of RNA therapeutics. Like any biotech company, its success depends on breakthrough scientific data. This indicator measures the overall bearish sentiment across the industry. When it's high, it indicates that investors are generally skeptical of the sector, fearing clinical trial failures or regulatory hurdles.
Shares shorted by the overall market
Avidity Biosciences (RNA) is a clinical-stage biotech company specializing in RNA therapeutics. When Short_All rises sharply, it signals market panic and risk aversion. This pessimism makes it nearly impossible for research-intensive, cash-burning companies like RNA to raise capital, jeopardizing their research.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Avidity Biosciences (RNA)
Avidity Biosciences is a clinical-stage biotech company working with RNA. Its shares are sensitive to trial news. This RNA stock can surge above 70 on positive R&D data. Oversold territory (<30) often reflects research setbacks or a general flight from the risky biotech sector.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Avidity-Biosciences-RNA&v=1772513556376 "RSI 14 indicator chart for the company's stock Avidity Biosciences (RNA)")
RSI 14 Market Segment - Dna
Avidity Biosciences (RNA) is developing a new class of drugs (AOCs) that combine the precision of antibodies with the power of RNA therapeutics. They target previously inaccessible genetic diseases. This chart tracks the collective sentiment in the DNA/RNA therapeutics sector. It helps investors understand whether the entire biotech segment is overheated by RNA hype or oversold by failed trials, providing context for Avidity.
RSI 14 for the overall market
Avidity Biosciences is a biotech company developing a new class of RNA-based drugs to treat rare muscle diseases. This cutting-edge research requires massive funding. This chart, reflecting investors' risk appetite, is critical for the company. Market panic is closing the window for raising capital needed to continue R&D.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast RNA (Avidity Biosciences)
Avidity Biosciences (RNA) is a biopharmaceutical company developing a new class of RNA therapeutics (AOC technology). The goal is to deliver RNA drugs to previously inaccessible tissues, such as muscle. This chart shows the average analyst forecast. It reflects their assessment of the breakthrough potential of the AOC platform and clinical trial data for the treatment of muscular dystrophies.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-RNA-Avidity-Biosciences&v=1772513556489 "A chart showing analyst consensus forecasts for the expected stock price. RNA (Avidity Biosciences)")
The difference between the consensus estimate and the actual stock price RNA (Avidity Biosciences)
Avidity Biosciences is a biotech company developing a new class of drugs (AOCs) designed to deliver RNA therapeutics into cells (e.g., muscle). This chart shows the difference between the consensus estimate and the price. It reflects analysts' belief in the breakthrough potential of this R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-RNA-Avidity-Biosciences&v=1772513556509 "A chart showing the difference between the consensus forecast and the actual stock price. RNA (Avidity Biosciences)")
Analyst consensus forecast for stock prices by market segment - Dna
Avidity Biosciences is a biotech company developing a new class of drugs (AOCs) that combine the precision of RNA therapeutics with antibody-based delivery. This chart shows analysts' overall expectations for the DNA/RNA sector. It reflects whether experts believe this complex but promising technology can achieve breakthroughs.
Analysts' consensus forecast for the overall market share price
Avidity Biosciences (RNA) is a biotech company developing a new class of drugs (AOC) that deliver RNA therapies to cells. It's a risky but disruptive business. This chart of overall market sentiment is important. Optimism = the market is willing to fund expensive clinical trials. Pessimism = risk aversion from unprofitable biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Avidity Biosciences
Avidity Biosciences is a biotech company developing a novel class of drugs (AOCs) that combine RNA therapeutics and antibodies to deliver the drug to a precise target (e.g., muscle). This chart represents a pure R&D bet. It reflects investors' confidence in their breakthrough platform and positive data from early clinical trials for the treatment of muscle diseases.
AKIMA Market Segment Index - Dna
Avidity Biosciences (RNA) is a next-generation biotech company pioneering AOC technology, which combines antibodies with RNA to deliver drugs into cells (e.g., muscle). This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does Avidity's breakthrough platform (AOC) differentiate it from the average pharma company?
The AKIM Index for the overall market
Avidity Biosciences is a biotech company developing RNA therapeutics. Its technology (AOC) enables drug delivery to previously inaccessible cells. It's a high-risk bet. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative scientific story compares to overall economic trends.
